Novo Nordisk exhibits the qualitative characteristics I prize most in a business: predictable demand (diabetes and obesity are chronic conditions requiring indefinite treatment), extraordinary pricing power (82% gross margins sustained over a decade), and a moat rooted in manufacturing complexity that cannot be replicated through capital alone. When I ask my standard question — can I predict this company's earnings in 2035 without heroic assumptions? — the answer is cautiously yes. Eight hundred million people with obesity and 540 million with diabetes will still need treatment in 2035, the biologic manufacturing barrier will still require years and billions to surmount, and the chronic nature of the therapy ensures that today's 46 million patients generate recurring revenue for the foreseeable future.</p><p>The competitive challenge from Eli Lilly is real and deserves honest acknowledgment. Novo Nordisk lost approximately 15 percentage points of relative market share in 2025 — this is not a trivial competitive setback. However, I distinguish between absolute decline (the business is shrinking) and relative deceleration (the business is growing but the market is growing faster). Novo Nordisk grew revenue to DKK 309 billion in 2025, its highest ever, and launched the Wegovy pill at twice the rate of any prior anti-obesity drug. A business growing at 10% while losing relative share in a 30% market is a business whose competitive position requires monitoring, not abandoning.</p><p>I would need Stage 2 to confirm that the current price of $36.53 provides adequate margin of safety against a normalized earnings base. My preliminary qualitative assessment is strongly positive — this is the type of business I want to own for decades, and the 48% decline from 2024 highs may represent precisely the kind of temporary sentiment overshoot that creates opportunity for patient capital.

Inverting the question as I always do: how does this investment lose money permanently? Three scenarios emerge. First, the VIE-style structural risk — but this is a Danish company listed on Copenhagen and NYSE, not a Chinese ADR, so corporate structure risk is negligible. Second, total competitive displacement — but Novo Nordisk has 62% volume share, the deepest pipeline in GLP-1, and the only oral peptide formulation approved for obesity. Third, permanent margin destruction — but 82% gross margins with 42% operating margins have proven resilient across thirteen years of varied competitive environments. I cannot construct a plausible scenario where an investor buying at a 48% discount from peak permanently loses capital.</p><p>What intrigues me about this situation is the psychology driving the selloff. The market correctly identified that Novo Nordisk is losing relative share to Eli Lilly — this is factual, not debatable. But the market then extrapolated this into a narrative of permanent decline, pricing the stock at 11.6x trailing earnings as if the obesity revolution never happened. This is textbook availability bias: the most recent data point (share loss) dominates the decision framework while structural advantages (manufacturing moat, chronic-disease patient base, pipeline depth) are dismissed. I have seen this pattern before — Costco periodically trades at seemingly expensive multiples and everyone panics, but the business quality carries the day.</p><p>The leadership transition is the one genuinely concerning qualitative factor. Two C-suite departures alongside a new CEO and a 9,000-person restructuring is more organizational churn than I am comfortable with. But the Novo Nordisk Foundation's controlling ownership provides long-term strategic stability that no activist or short-term pressure can disrupt — a governance feature I typically value highly.

I categorically avoid healthcare, pharma, and biotech despite my medical degree — precisely because of it. Having trained at Harvard Medical School and studied the biology of disease, I understand better than most that clinical outcomes are not predictable over 5-10 year horizons. The GLP-1 story illustrates my concern perfectly: five years ago, semaglutide was an uncontested monopoly. Today, tirzepatide has demonstrated clinically superior weight loss, and over 100 molecules are in development. Three years from now, a small-molecule oral GLP-1 agonist from Lilly, Amgen, or Viking could render Novo Nordisk's $131 billion manufacturing investment in biologic fermentation capacity partially obsolete. This is not a toll booth where the underlying activity cannot occur without paying Novo Nordisk's toll — physicians can and do prescribe competing GLP-1 therapies, and patients switch when efficacy data favors alternatives.</p><p>The moat in pharmaceuticals is fundamentally R&D-dependent, which means it requires constant reinvention rather than compounding automatically. Compare this to my holdings — FICO, Moody's, Visa, MSCI — where the competitive advantage is structural and self-reinforcing. Every mortgage in America requires a FICO score regardless of who develops a better scoring algorithm. Every bond needs a Moody's or S&P rating regardless of whether a competitor offers ratings for free. There is no pharmaceutical equivalent of this inevitability. A physician's prescription is a choice, not a structural requirement, and choices can shift with a single clinical trial readout.</p><p>I admire the business quality — 82% gross margins and 42% operating margins are exceptional by any standard. But my framework demands 10-year visibility on competitive positioning, and I cannot see 10 years ahead in GLP-1 therapeutics with any confidence. The prudent course is to own businesses where success is inevitable rather than merely probable.

This is the kind of setup I live for — a dominant business at a sentiment extreme. The stock has declined 48% from its 2024 highs while the business generated DKK 309 billion in revenue, launched a record-breaking new product, and maintained 42% operating margins. The market is pricing Novo Nordisk at 11-12x trailing earnings, the lowest multiple since the pre-GLP-1 era when the company was stagnating. But the business today is fundamentally different from 2016 — it has an $82 billion obesity franchise that did not exist, a pipeline with three product generations, and a manufacturing capacity that no competitor can match for years.</p><p>The catalyst pipeline is what makes this actionable now rather than a wait-and-see situation. Wegovy HD just received FDA approval (March 20, 2026). REDEFINE 4 head-to-head data against tirzepatide was released in February. CagriSema is under FDA review. Medicare obesity coverage activates mid-2026. The Wegovy pill is scaling at record pace. These are independent catalysts — any one of them could trigger a re-rating, and multiple firing simultaneously could drive a substantial move. When I see this many near-term catalysts at a trough multiple, the asymmetric math overwhelmingly favors being long.</p><p>The bears are right that Novo Nordisk is losing relative share to Lilly. But they are wrong that this is permanent. The competitive dynamics in pharmaceuticals are generational — whoever has the best current molecule wins new patient starts, and Novo Nordisk's pipeline (CagriSema, zenagamtide) is specifically designed to recapture clinical differentiation. I would rather own the stock now at 12x and wait for the pipeline to deliver than buy at 20x after the market already prices in the catalysts.

Applying my moat trajectory framework, Novo Nordisk presents a fascinating case study in the distinction between a wide moat and a widening moat. The moat is unquestionably wide — 62% global volume share, biologic manufacturing barriers, 82% gross margins, 46 million chronic-condition patients — but the trajectory is narrowing, not widening. The 15-percentage-point relative share loss in 2025 is the clearest evidence: competitors are moving faster than Novo Nordisk, which is the rowing boat analogy I use at conferences. However, I distinguish between moat narrowing due to execution failure (permanent) and moat narrowing due to an investment transition period (temporary). The Wegovy pill launch — record-breaking uptake from patients new to GLP-1 therapy — suggests the franchise can still create new demand categories, which is a widening characteristic even as injectable share narrows.</p><p>My concern centers on the Vinall Myth #3 application: is Novo Nordisk's moat the output of ongoing execution, or a legacy asset being depleted? The century of metabolic disease expertise, the biologic manufacturing infrastructure, and the clinical trial database are genuine structural advantages. But the 2025 margin compression and the C-suite departures introduce doubt about whether current management is executing to widen the moat or merely defending it. The hiring of Jamey Millar from Optum (payer expertise) and Hong Chow from Merck (global portfolio strategy) suggests strategic intentionality, but these executives are weeks into their roles.</p><p>The founder/owner-operator dimension is complicated by the Novo Nordisk Foundation structure. The Foundation provides the long-term strategic stability I value but eliminates the founder-driven urgency that characterizes my best investments (Interactive Brokers with Thomas Peterffy, Carvana with Ernie Garcia). I would pass the sledgehammer test on the institutional culture but not on any individual leader — which creates a dependency on institutional rather than personal quality.

Interesting business. The qualitative characteristics are impressive — 82% gross margins, chronic disease patient retention, biologic manufacturing barriers that take a decade to replicate. If I encountered this business at $30-40 billion market cap, I would be extremely interested. The 48% decline from peak creates the kind of sentiment extreme where I typically find my best ideas.</p><p>But I cannot form a definitive view until I see the price in the context of my framework. Quality without price is meaningless in my approach. My explicit rule is that any business above $100 billion market cap cannot deliver the 3:1 asymmetric returns I require. At $162 billion, Novo Nordisk would need to triple to approximately $490 billion — implying roughly 35-40x current earnings. While not mathematically impossible for a franchise pharmaceutical company in a rapidly expanding market, it requires assumptions that I am uncomfortable making.</p><p>The one qualitative factor that could potentially override my size concern is the severity of the sentiment dislocation. A business that has declined 48% while maintaining 42% operating margins and launching record-breaking products is displaying the kind of market mispricing where the fear is disconnected from the fundamentals. Stage 2 will determine whether the P/E and market cap gates allow engagement or require me to admire from a distance.

My investment framework asks one question above all others: can this business survive and thrive through the worst conceivable adversity? For Novo Nordisk, the worst conceivable adversity is not a recession or a management failure — it is a competitive displacement where a next-generation molecule renders the entire semaglutide manufacturing infrastructure less valuable. This is not hypothetical: Eli Lilly's tirzepatide achieved clinical superiority within three years of Ozempic's peak, and Amgen's MariTide, Viking's VK2735, and Lilly's retatrutide are all approaching late-stage development with differentiated profiles. The company's response — investing DKK 131 billion in manufacturing capacity for a molecule that may face clinical obsolescence — could prove to be the most expensive bet in pharmaceutical history if next-generation competition arrives faster than expected.</p><p>I apply a Darwinian lens to industry change rates. My preferred investments are in slow-changing environments — Asian Paints competing in Indian house paint, HDFC Bank providing mortgages to Indian homebuyers — where the competitive landscape evolves over decades, not years. The GLP-1 therapeutics market has transformed from a one-player market (Novo Nordisk with semaglutide) to a two-player market (adding Lilly with tirzepatide) in three years, and will become a five-to-seven player market by 2030. This rate of competitive evolution is faster than my framework can accommodate. Businesses that survive in fast-changing environments do so through constant innovation — exactly the R&D-dependent moat renewal that I avoid because it requires heroic management rather than structural advantage.</p><p>I acknowledge the business quality is exceptional by current metrics, and the 48% stock decline may represent genuine opportunity for investors with different frameworks. But my portfolio construction requires businesses where I can hold for 10-20 years without monitoring competitive dynamics quarterly, and Novo Nordisk does not pass that test.